Big Growth in CRAMS Contracts for Jubilant

Jubilant Organosys (Noida), one of India’s largest drug discovery and pharma services companies, says it has signed several custom research and manufacturing services (CRAMS) contracts worth a combined $60 million. The value of the deals represents a 50% increase over deals signed last year. Jubilant says that almost $54 million worth of contracts are with European and U.S. firms, and include deals with unspecified life science multinationals. “We will continue to focus on investments in innovation and world-class manufacturing facilities,” says...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers